GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Veru Inc.
Veru is a biopharmaceutical company whose shares have seen ups and downs on news of its COVID-19 treatment. Its price chart is a prime example of the high volatility and speculation in biotech, where the focus has now shifted to its oncology drugs.
Share prices of companies in the market segment - Cancer cure
Veru Inc. is an oncology company developing drugs to treat breast and prostate cancer. We've categorized it as a "Cancer Treatment" company. The chart below shows how investors value companies focused on hormone-dependent tumors and new therapies.
Broad Market Index - GURU.Markets
Veru is an oncology company developing drugs to treat breast and prostate cancer. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
VERU - Daily change in the company's share price Veru Inc.
Veru Inc.'s daily price change reflects the high volatility inherent in oncology companies. It reflects investor reactions to news about clinical trials of its cancer treatments and is an important metric for assessing risk.
Daily change in the price of a set of shares in a market segment - Cancer cure
Veru Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with VERU's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Veru is a pharmaceutical company focused on oncology and respiratory diseases. Its shares are known for their high volatility on clinical trial news. These sharp movements are part of a market dynamic driven by hopes for new breakthrough drugs.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Veru Inc.
Veru Inc.'s year-over-year performance is a story of its transition from men's health to oncology. Its 12-month market cap is crucially dependent on clinical trial data for its breast cancer drug. Its valuation is a bet that this strategic pivot will be successful after the failure of its COVID-19 drug.
Annual dynamics of market capitalization of the market segment - Cancer cure
Veru Inc. is a biopharmaceutical company focused on developing cancer treatments. Its stock price is extremely volatile, reflecting both the potential of its R&D and the setbacks in clinical trials typical of this speculative sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Veru is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Veru Inc.
Veru is an oncology company developing cancer treatments. Its monthly performance is highly volatile and depends on the results of its clinical trials. News about data on its key drugs in breast and prostate cancer treatment programs causes sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Veru is an oncology company developing drugs to treat breast and prostate cancer. Its success depends on clinical trial results and regulatory approval. The chart below illustrates the overall dynamics of the cancer drug development sector, where the stakes are always high.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Veru Inc. is an oncology company developing cancer treatments. Its shares are highly volatile, depending on clinical trial news and regulatory decisions. The company often attracts the attention of speculators, and its movements don't correlate with overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Veru Inc.
The short-term price volatility of Veru, a biopharmaceutical company focused on oncology, is very high. News about clinical trials of its drugs for breast and prostate cancer is a key driver of sharp price movements.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Veru and the entire oncology biotech sector are riding the wave of industry-wide news and sentiment. Breakthroughs in cancer treatments or changes in FDA policy could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Veru and the entire oncology biotech sector are riding the wave of industry-wide news and sentiment. Breakthroughs in cancer treatments or changes in FDA policy could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Market capitalization of the company, segment and market as a whole
VERU - Market capitalization of the company Veru Inc.
Veru's market capitalization is the financial valuation of a biopharmaceutical company focused on oncology and COVID-19 treatments. The chart reflects both the potential of its oncology developments and the dramatic rise and fall of its COVID-19 drug announcement. Its dynamics offer a cautionary tale of biotech hype and regulatory realities.
VERU - Share of the company's market capitalization Veru Inc. within the market segment - Cancer cure
Veru Inc. is a biopharmaceutical company focused on developing drugs to treat cancer and protect against COVID-19. Its market share reflects both the value of its oncology portfolio and the high volatility associated with COVID-19 drugs. The chart below shows how the market is pricing this dual focus.
Market capitalization of the market segment - Cancer cure
Veru is an oncology company focused on breast and prostate cancer treatment. The chart below shows the overall market capitalization of the entire sector. Its dynamics reflect the constant search for new treatments. Veru, like many others, is navigating the challenging path of clinical trials in hopes of success.
Market capitalization of all companies included in a broad market index - GURU.Markets
Drug development, as seen on the chart, can target a variety of diseases. Veru Inc. has a pipeline of developments in oncology and viral infection treatments. Its market cap, notoriously volatile, reflects both the promise and failure of its clinical programs.
Book value capitalization of the company, segment and market as a whole
VERU - Book value capitalization of the company Veru Inc.
Veru's chart represents the financial base for oncology drug development. Its book value reflects investments in clinical trials of its candidates for breast and prostate cancer, as well as in the production of the FC2 female condom.
VERU - Share of the company's book capitalization Veru Inc. within the market segment - Cancer cure
Veru Inc., a biopharmaceutical company, focuses on oncology and respiratory diseases. Its sector assets include R&D and manufacturing facilities, including a plant producing the FC2 female condom, which generates stable revenue.
Market segment balance sheet capitalization - Cancer cure
Veru Inc. is an oncology company. Its model becomes increasingly capital-intensive as its products approach market, requiring investments in production and commercial infrastructure. Compared to the pharmaceutical sector, its balance sheet reflects the transition from a "light" R&D phase to a more "heavy" commercial phase.
Book value of all companies included in the broad market index - GURU.Markets
Veru's assets are not a broad portfolio, but rather a focused effort on developing new drugs for the treatment of prostate and breast cancer. The company's balance sheet reflects the value of its leading clinical programs. The chart shows how much capital is invested in fighting the most common types of cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Veru Inc.
Veru Inc. is an oncology and urology company. Its market capitalization reflects investors' valuation of its pipeline, including commercialized products and late-stage candidates. This valuation reflects both current sales and future potential.
Market to book capitalization ratio in a market segment - Cancer cure
Veru Inc. is an oncology company focused on breast and prostate cancer treatment. Its valuation is heavily dependent on the success of its lead drugs. This chart illustrates the volatility typical of biotech companies, where market capitalization can fluctuate sharply based on clinical trial news.
Market to book capitalization ratio for the market as a whole
Veru is an oncology company developing drugs for the treatment of breast and prostate cancer. Its value is determined by the potential of its scientific developments and the success of clinical trials. This chart demonstrates how market valuations in biotech are a bet on future scientific breakthroughs rather than on current tangible assets.
Debts of the company, segment and market as a whole
VERU - Company debts Veru Inc.
Veru Inc. is an oncology company developing drugs to treat breast and prostate cancer. Advancing candidates through late-stage clinical trials is extremely expensive. This chart shows how the company uses funding to support this critical research.
Market segment debts - Cancer cure
Veru Inc. is an oncology company developing drugs for the treatment of breast and prostate cancer. Its financial strategy is directly tied to the stage of its clinical development. This chart shows how the company funds its key research and manages its balance sheet as it moves toward potential commercialization of its products.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Veru Inc.
Veru Inc., a biopharmaceutical company focused on oncology and viral disease treatments, shows its debt load. With its high debt levels, the company experiences ups and downs related to trial results, and unexpected results could either save it or completely sink it under the weight of its liabilities.
Market segment debt to market segment book capitalization - Cancer cure
Veru Inc. is an oncology company focused on developing drugs to treat breast and prostate cancer. This chart compares its debt raised to fund clinical trials to the overall market capitalization of the entire sector. It helps assess how the company is funding its fight against hormone-dependent cancers.
Debt to book value of all companies in the market
Veru Inc. is an oncology company developing cancer treatments. After receiving approvals, the company requires funding for marketing and manufacturing. The chart shows how Veru uses debt financing to commercialize its products. A comparison with the pharmaceutical market helps assess the success of its transition from R&D to sales.
P/E of the company, segment and market as a whole
P/E - Veru Inc.
For Veru, a company focused on cancer treatment, this chart represents the valuation of its lead drug. The price-to-earnings ratio reflects how investors assess its commercial potential in the competitive oncology market. The price-to-earnings ratio reflects the drug's sales reports and new clinical trial results.
P/E of the market segment - Cancer cure
This chart reflects the average valuation for the biopharmaceutical sector—the benchmark for Veru. Comparison with this metric helps investors understand how the market views the company's drug prospects relative to competitors. A below-average valuation may indicate doubts about their commercial potential or patent risks.
P/E of the market as a whole
Veru is an oncology company developing drugs to treat breast and prostate cancer. It also gained notoriety during the pandemic for its work on a COVID-19 treatment. This chart shows sentiment in the biotech sector. It helps understand how the market values the company's core oncology portfolio and how news about its other programs impacts volatility and valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Veru Inc.
Veru is an oncology biopharmaceutical company developing drugs for the treatment of breast and prostate cancer. This chart reflects analyst expectations for its clinical programs. It is an indicator of the market's confidence that one of its candidates will successfully complete trials and become a viable treatment option.
%20P%2FE%20Veru%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Veru-Inc.&v=1772647758102 "Chart of the company's future (projected) P/E Veru Inc.")
Future (projected) P/E of the market segment - Cancer cure
Veru Inc. is an oncology company developing drugs to treat breast and prostate cancer. This chart compares its future profitability expectations with those of the pharmaceutical sector. It helps understand how the market views its pipeline of candidates and its transition from a women's health company to a focused oncology player.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772647758179 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Veru is an oncology company focused on breast and prostate cancer treatments. This chart shows the company's overall risk appetite. Veru's success depends on the commercial success of its drugs and the results of clinical trials. This is a story driven by science and sales, not by general market sentiment.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772647758304 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Veru Inc.
Veru is an oncology biopharmaceutical company developing new drugs for the treatment of breast and prostate cancer. This chart illustrates the company's financial trajectory in late-stage clinical development. The results reflect investments in research and preparation for potential commercialization.
Profit of companies in the market segment - Cancer cure
Veru is an oncology biopharmaceutical company developing drugs for the treatment of breast and prostate cancer. The company also has a commercial product for women's health. This chart illustrates the financial climate in the oncology sector, which is characterized by both high research costs and the potential for huge revenues from successful drugs.
Overall market profit
Veru Inc. is an oncology company developing drugs to treat breast and prostate cancer. Demand for its products is driven by medical needs, not economic cycles. This provides potential revenue stability. However, prior to commercialization, the company relies on investment, which is easier to attract in a healthy economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Veru Inc.
Veru is an oncology company developing drugs for the treatment of breast and prostate cancer. The company also has a commercial product—a female condom. This chart represents the combined sales expectations of its existing product and the likely success of its oncology developments.
%20profit%20of%20the%20company%20Veru%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Veru-Inc.&v=1772647758506 "Graph of future (projected) profit of the company Veru Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Veru Inc. is an oncology company focused on developing new treatments for breast and prostate cancer. This chart shows forecasts for the biotech sector. Veru's profitability depends on the success of its drugs in late-stage clinical trials and their ability to address significant unmet needs in the treatment of these common cancers.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772647758529 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Veru Inc. is a biopharmaceutical company focused on oncology and COVID-19 treatment. Its success depends on regulatory approval and subsequent commercialization of its drugs. This earnings forecast chart influences the overall investment climate and market willingness to fund companies whose revenue depends on several key products.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772647758622 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Veru Inc.
Veru Inc. is an oncology company developing drugs for the treatment of breast and prostate cancer. This chart shows how the market views its revenue and the potential of its clinical development pipeline. The dynamics are heavily dependent on research news and the commercial prospects of its oncology portfolio.
P/S market segment - Cancer cure
Veru Inc. is an oncology company developing drugs for the treatment of breast and prostate cancer. The company also has a commercial business producing female condoms. This chart reflects the average valuation in the pharmaceutical industry, helping to understand how the market values both Veru's oncology research and its commercial product.
P/S of the market as a whole
Veru Inc. is an oncology company developing drugs for the treatment of breast and prostate cancer. Its revenue depends on the successful commercialization of its products. This chart helps assess the market perception of the company's current revenue and its potential for developing new drugs in the highly competitive field of oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Veru Inc.
Veru is an oncology company developing drugs for the treatment of breast and prostate cancer. This chart reflects investor expectations for the future success of its clinical programs. The valuation is based on the potential revenue from its pipeline of drugs targeting large and commercially attractive markets.
%20P%2FS%20Veru%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Veru-Inc.&v=1772647758756 "The graph of the company's future (projected) P/S Veru Inc.")
Future (projected) P/S of the market segment - Cancer cure
Veru Inc. is an oncology company focused on developing drugs for the treatment of prostate and breast cancer. This chart compares the company's future revenue expectations with its industry. It reflects the market's valuation of its pipeline of drug candidates and confidence in the success of its clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772647758762 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Veru Inc. is an oncology biopharmaceutical company developing drugs to treat breast and prostate cancer. This chart shows overall revenue expectations, as Veru works to address pressing challenges in oncology. The success of its drugs could offer new options for millions of patients and impact the outlook for the entire sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772647758791 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Veru Inc.
Veru Inc. is an oncology company focused on developing drugs to treat breast and prostate cancer. Its revenue, shown in this chart, is generated primarily by sales of the FC2 female condom, which provides funding for its core oncology research.
Sales of companies in the market segment - Cancer cure
Veru Inc. is a biopharmaceutical company focused on developing drugs to treat breast and prostate cancer, as well as to combat viral threats. This chart illustrates the dynamics of the pharmaceutical sector, where companies working on socially significant diseases are attracting significant attention and investment.
Overall market sales
Veru Inc. is an oncology biopharmaceutical company developing cancer treatments. Its operations require a constant influx of capital for research. The growth in total economic revenue, reflected in this chart, improves investor sentiment, making them more willing to fund innovative but risky biotech companies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Veru Inc.
Veru Inc. is an oncology company developing drugs for the treatment of breast and prostate cancer. The company's future revenue depends on the success of its clinical programs and the commercialization of its developments. This chart reflects analyst expectations for key developments in the company's pipeline and potential demand for its drugs.
%20sales%20of%20the%20company%20Veru%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Veru-Inc.&v=1772647758941 "Schedule of future (projected) sales of the company Veru Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Veru Inc. is an oncology company developing new drugs for the treatment of breast and prostate cancer. This chart shows forecasts for the cancer treatment sector. It provides context for assessing how Veru's drugs, with their novel mechanisms of action, could become standard treatments for these common diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772647758956 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Veru Inc., an oncology and pharmaceutical company, sees this chart as an indicator of the overall health of the sector. The optimistic economic forecasts reflected here are fueling increased R&D funding and M&A deals, creating a favorable environment for the development and commercialization of their research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772647758981 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Veru Inc.
Veru is a biopharmaceutical company focused on developing drugs to treat cancer and viral diseases. This chart shows how successfully the company is commercializing its products. It reflects Veru's ability to convert drug sales revenue into net profit after covering manufacturing, marketing, and research expenses.
Market segment marginality - Cancer cure
Veru Inc. is an oncology company developing drugs for the treatment of breast and prostate cancer. It previously also developed women's health products. For such a company, efficiency means the ability to focus and successfully advance its key oncology programs while managing R&D and commercialization costs.
Market marginality as a whole
Veru Inc. is an oncology biopharmaceutical company developing drugs for the treatment of breast and prostate cancer. This chart shows average profitability, and Veru targets hormone-sensitive cancers. Their profitability will depend on the successful commercialization of their drugs after receiving regulatory approval.
Employees in the company, segment and market as a whole
Number of employees in the company Veru Inc.
Veru Inc. is an oncology company developing drugs for the treatment of prostate and breast cancer. This chart shows its team managing clinical trials and preparing for commercialization. The staff dynamics reflect the progress of its key therapeutic programs.
Share of the company's employees Veru Inc. within the market segment - Cancer cure
Veru Inc. is an oncology company developing new drugs for the treatment of prostate and breast cancer. This chart shows the percentage of all scientists and clinicians working in this therapeutic area that Veru employs. This reflects its scientific focus and the scale of its clinical programs targeting hormone-dependent tumors.
Number of employees in the market segment - Cancer cure
Veru is an oncology company developing drugs for the treatment of breast and prostate cancer. Its staff consists of scientists and clinical development specialists. This chart shows its focused activities. The dynamics of its staff reflect the progress of clinical trials and the company's efforts to bring its drugs to market.
Number of employees in the market as a whole
Veru Inc. is an oncology company developing drugs to treat breast and prostate cancer. Demand for effective cancer drugs is enormous and unaffected by economic cycles. This chart reflects overall employment, but for Veru and its patients, only clinical trial results matter.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Veru Inc. (VERU)
Veru is an oncology company with products on the market and in development. This metric reflects both the value of its intellectual property and the availability of its commercial infrastructure. The graph shows the balance between R&D and sales effectiveness.
%20of%20the%20company%20Veru%20Inc.%20(VERU)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Veru-Inc.-VERU&v=1772647759336 "Chart of market capitalization per employee (in thousands of dollars) of the company Veru Inc. (VERU)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Veru Inc. is an oncology company developing drugs for the treatment of breast and prostate cancer. Its market valuation depends on the success of clinical trials and the future commercial potential of its drugs. This chart compares investor confidence in its product portfolio per employee compared to its competitors.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772647759457 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Veru is an oncology biopharmaceutical company developing drugs for the treatment of breast and prostate cancer. The company has products in late-stage development. This chart reflects how investors assess the potential of the company's pipeline, where success in clinical trials could lead to commercial launches and significant growth.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772647759505 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Veru Inc. (VERU)
Veru Inc. is a biopharmaceutical company focused on developing cancer treatments (breast and prostate). They also have a commercial product (the FC2 female condom). This chart shows how successfully the company finances its expensive R&D with FC2 profits and how much it spends on research per employee.
%20Chart%20Veru%20Inc.%20(VERU)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Veru-Inc.-VERU&v=1772647759540 "Company Profit Per Employee (in thousands of dollars) Chart Veru Inc. (VERU)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Veru (VERU) is a biopharmaceutical company focused on developing drugs to treat oncology conditions (breast and prostate cancer) and to protect against COVID-19. This chart reflects the effectiveness of their dual strategy. It shows how the company generates revenue from existing products (e.g., female condoms) while simultaneously advancing R&D candidates.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772647759690 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Veru Inc. is an oncology company developing drugs for the treatment of breast and prostate cancer. The company previously had commercial products (FC2 condoms), but its focus has shifted to R&D. This chart reflects this transformation. Earnings per employee will be determined by the balance between the costs of very expensive clinical trials and potential revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772647759712 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Veru Inc. (VERU)
Veru is an oncology biopharmaceutical company developing drugs for the treatment of breast and prostate cancer. This graph illustrates their journey from research to sales. Increasing revenue per employee will reflect a successful new drug launch and the effectiveness of a small but focused commercial team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Veru-Inc.-VERU&v=1772647759743 "Sales chart per company employee Veru Inc. (VERU)")
Sales per employee in the market segment - Cancer cure
Veru Inc. is an oncology company developing drugs for the treatment of breast and prostate cancer. They were previously known for their female condom. This chart shows the average revenue per employee in the sector. It helps assess how productive Veru's R&D and commercial teams are in promoting their oncology drugs.
Sales per employee for the market as a whole
Veru Inc. (VERU) is a biopharmaceutical company focused on oncology (breast cancer, prostate cancer) and COVID-19 treatment. They have several late-stage drugs. This chart shows the current revenue (from spinoffs) per employee while the company awaits approval of its lead drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Veru Inc. (VERU)
Veru is a biopharmaceutical company whose key prostate cancer drug, Sabizabulin, was also tested against COVID-19 but was rejected by the FDA. This chart shows the number of investors who have lost faith in the company. They are betting that its oncology program will also fail, and that the shares, which soared on the "COVID hype," are worthless.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Veru-Inc.-VERU&v=1772647759876 "Short Shares Chart for the Company Veru Inc. (VERU)")
Shares shorted by market segment - Cancer cure
Veru Inc. is a biotech company focused on oncology. This indicator measures overall skepticism in the pharmaceutical industry. When it's high, it suggests that investors generally don't believe clinical trials will be successful or anticipate funding problems, which is a risk for the entire industry in the early stages.
Shares shorted by the overall market
Veru Inc. is a biotech company focused on oncology and women's health. The company has experienced ups and downs related to drug development. This chart illustrates the overall market pessimism. When fear mounts, investors are especially merciless toward companies whose previous promises (such as a Covid treatment) have failed to materialize. VERU is becoming a sell-off target due to doubts about its future.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Veru Inc. (VERU)
Veru Inc. is an oncology company developing drugs to treat breast and prostate cancer. The company has previously attracted attention for its COVID-19 research. This oscillator shows how these waves of news hype led to extreme overbought levels (above 70), followed by deep declines into oversold levels (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Veru-Inc.-VERU&v=1772647759920 "RSI 14 indicator chart for the company's stock Veru Inc. (VERU)")
RSI 14 Market Segment - Cancer cure
Veru (VERU) is a "biotech" (oncology, COVID). Their portfolio includes drugs for *cancer* (prostate, breast) and (previously) COVID-19. The "Cancer cure" (biotech) sector thrives on news. RSI\_14\_Seg shows the "temperature" of this *entire* segment. It's vital to understand: is VERU's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Veru Inc. (VERU) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VERU (Veru Inc.)
Veru is a biopharmaceutical company focused on cancer treatment (prostate cancer, breast cancer). This chart shows the average 12-month analyst price target. Their target price reflects their collective assessment of the likelihood of clinical trial success and approval of their oncology drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VERU-Veru-Inc.&v=1772647759959 "A chart showing analyst consensus forecasts for the expected stock price. VERU (Veru Inc.)")
The difference between the consensus estimate and the actual stock price VERU (Veru Inc.)
Veru is a biopharmaceutical company focused on developing treatments for cancer (prostate and breast) and respiratory diseases (COVID-19). This chart measures the gap between the current share price and the consensus target price. It shows how confident experts are in their R&D pipeline, particularly their oncology drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VERU-Veru-Inc.&v=1772647759983 "A chart showing the difference between the consensus forecast and the actual stock price. VERU (Veru Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Veru is a biotech company focused on developing drugs to treat breast and prostate cancer. Its success depends entirely on R&D and FDA approval. This chart shows analysts' overall expectations for the entire cancer treatment sector. It reflects whether experts believe risky R&D bets in oncology will be successful.
Analysts' consensus forecast for the overall market share price
Veru Inc. is a biopharmaceutical company focused on developing cancer treatments (prostate and breast). The company was previously known for producing female condoms. This chart shows the company's overall risk appetite. For Veru, a company in transition with high-risk clinical trials, overall market optimism is critical for raising capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Veru Inc.
Veru is a biopharmaceutical company undergoing a major pivot. While they have an established commercial product (the FC2 female condom), their true focus is on their oncology R&D pipeline. This chart is an integral indicator of this high-stakes transition. It reflects their efforts to translate their drug candidates into cancer treatments after a high-profile setback in COVID-19.
AKIMA Market Segment Index - Cancer cure
Veru Inc. (VERU) is an oncology company focused on developing drugs for the treatment of breast and prostate cancer. The company previously also developed a COVID-19 treatment. The chart shows the average index for the segment, helping investors assess how Veru's risks and potential in treating hormone-dependent tumors compare to the sector average.
The AKIM Index for the overall market
Veru is a biopharmaceutical company developing drugs for oncology (breast cancer) and viral diseases. It also has a women's health business. This chart, reflecting the market average, provides a macro backdrop. It helps assess how VERU, which is shifting its focus to metabolism (muscle), compares to overall trends.
